Pediatric Hodgkin Lymphoma Differential Diagnoses

  • Author: Pedro A de Alarcon, MD; Chief Editor: Robert J Arceci, MD, PhD   more...
 
Updated: Oct 19, 2011
 
 
 
Contributor Information and Disclosures
Author

Pedro A de Alarcon, MD  William H Albers Professor and Chair, Department of Pediatrics, University of Illinois College of Medicine at Peoria

Pedro A de Alarcon, MD is a member of the following medical societies: American Academy of Pediatrics, American Association for the Advancement of Science, American Federation for Clinical Research, American Pediatric Society, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Children's Oncology Group, Eastern Society for Pediatric Research, International Society for Experimental Hematology, International Society of Hematology, International Society on Thrombosis and Haemostasis, Medical Society of the State of New York, National Hemophilia Foundation, New York Academy of Sciences, Society for Pediatric Research, Southern Society for Pediatric Research, and Virginia Chapter of the American Academy of Pediatrics and the Virginia Pediatric Society

Disclosure: Nothing to disclose.

Coauthor(s)

Mohamad M Al-Rahawan, MD, MPH  Assistant Professor of Pediatrics, Pediatric Hematology/Oncology Student, Resident, and Visiting Fellow Rotation Director, University of Illinois College of Medicine at Peoria; Adjunct Faculty, St Jude Children's Research Hospital; Attending Pediatric Hematologist/Oncologist, Children's Hospital of Illinois, OSF-St Francis Medical Center; Staff Physician, St Jude Midwest Affiliate

Mohamad M Al-Rahawan, MD, MPH is a member of the following medical societies: American Society of Hematology, American Society of Pediatric Hematology/Oncology, and Children's Oncology Group

Disclosure: Nothing to disclose.

Monika Metzger, MD, MSc  Assistant Professor, University of Tennessee School of Medicine; Assistant Member, Department of Oncology, Division of Leukemia and Lymphoma, St Jude Children's Research Hospital

Monika Metzger, MD, MSc is a member of the following medical societies: Children's Oncology Group

Disclosure: Nothing to disclose.

Specialty Editor Board

Kathleen M Sakamoto, MD, PhD  Professor and Chief, Division of Hematology-Oncology, Vice-Chair of Research, Mattel Children's Hospital at UCLA; Co-Associate Program Director of the Signal Transduction Program Area, Jonsson Comprehensive Cancer Center, California Nanosystems Institute and Molecular Biology Institute, University of California, Los Angeles, David Geffen School of Medicine

Kathleen M Sakamoto, MD, PhD is a member of the following medical societies: American Society of Hematology, American Society of Pediatric Hematology/Oncology, International Society for Experimental Hematology, Society for Pediatric Research, and Western Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Steven K Bergstrom, MD  Department of Pediatrics, Division of Hematology-Oncology, Kaiser Permanente Medical Center of Oakland

Steven K Bergstrom, MD is a member of the following medical societies: Alpha Omega Alpha, American Society of Clinical Oncology, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Children's Oncology Group, and International Society for Experimental Hematology

Disclosure: Nothing to disclose.

Chief Editor

Robert J Arceci, MD, PhD  King Fahd Professor of Pediatric Oncology, Professor of Pediatrics, Oncology and the Cellular and Molecular Medicine Graduate Program, Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine

Robert J Arceci, MD, PhD is a member of the following medical societies: American Association for Cancer Research, American Association for the Advancement of Science, American Pediatric Society, American Society of Hematology, and American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

References
  1. Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood. Jun 15 2005;105(12):4553-60. [Medline].

  2. Arya LS, Dinand V. Current strategies in the treatment of childhood Hodgkins disease. Indian Pediatr. Nov 2005;42(11):1115-28. [Medline].

  3. Percy CL, Smith MA, Linet M, et al. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995: Lymphomas and Reticuloendothelial Neoplasms [Surveillance, Epidemiology, and End Results Web site]. November 5, 1999. National Cancer Institute: Surveillance Epidemiology and End Results. Available at http://www.seer.cancer.gov.

  4. Robertson VL, Anderson CS, Keller FG, et al. Role of FDG-PET in the Definition of Involved-Field Radiation Therapy and Management for Pediatric Hodgkin's Lymphoma. Int J Radiat Oncol Biol Phys. Jun 1 2011;80(2):324-32. [Medline].

  5. Harris NL. Hodgkin's disease: classification and differential diagnosis. Mod Pathol. Feb 1999;12(2):159-75. [Medline].

  6. Kuppers R, Yahalom J, Josting A. Advances in biology, diagnostics, and treatment of Hodgkin's disease. Biol Blood Marrow Transplant. Jan 2006;12(1 Suppl 1):66-76. [Medline].

  7. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, Fourth Edition. Vol 2. 4th ed. Lyon, France: IARC Press; 2008.

  8. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. Jan 2009;9(1):15-27. [Medline].

  9. Ng AK, Mauch PM. Late effects of Hodgkin's disease and its treatment. Cancer J. Mar-Apr 2009;15(2):164-8. [Medline].

  10. Cheson BD, Bartlett NL. Hodgkin Lymphoma: New Drug Breakthroughs. Medscape News Today. Available at http://www.medscape.com/viewarticle/733776. Accessed September 18, 2011.

  11. Al-Rahawan MM, A de Alarcón PA. Gemcitabine and vinorelbine therapy for patients with Hodgkin lymphoma. Pediatric Health. Dec 2009;3(6):525-32.

  12. Shankar A, Visaduraki M, Hayward J, Morland B, McCarthy K, Hewitt M. Clinical outcome in children and adolescents with Hodgkin lymphoma after treatment with chemotherapy alone - The results of the United Kingdom HD3 national cohort trial. Eur J Cancer. Jun 22 2011;[Medline].

  13. Küppers R. Molecular biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009;491-6. [Medline].

  14. Glaser SL, Clarke CA, Nugent RA, Stearns CB, Dorfman RF. Social class and risk of Hodgkin's disease in young-adult women in 1988-94. Int J Cancer. Mar 1 2002;98(1):110-7. [Medline].

  15. Deutsch YE, Tadmor T, Podack ER, Rosenblatt JD. CD30: an important new target in hematologic malignancies. Leuk Lymphoma. Sep 2011;52(9):1641-54. [Medline].

  16. Böll B, Bredenfeld H, Görgen H, et al. Phase II study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood. Sep 13 2011;[Medline].

  17. Straus DJ, Johnson JL, LaCasce AS, et al. Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET. Blood. May 19 2011;117(20):5314-20. [Medline].

Previous
Next
 
Mixed cellularity Hodgkin lymphoma showing both mononucleate and binucleate Reed-Sternberg cells in a background of inflammatory cells (hematoxylin and eosin, original magnification X200).
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.